Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic hydrocortisone
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-15 of 15 for your search:
Start Over
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 80
Sponsor: Other
Protocol IDs: TAC-HCC, NCT02240771
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, R37CA036401, 5R01CA090246, Aspar PK-PD-T16, NCI-2011-01254, NCT00549848
Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I 68905, RPCI-I-68905, NCT00536991
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 24 and under
Sponsor: Other
Protocol IDs: SELHEM, NCI-2014-01704, NCT02212561
Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFZ008, 2014-001633-84, NCT02303821
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 24
Sponsor: Other
Protocol IDs: JALSG ALL202-U, NCT00131053
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 0810010067, J591+Ketoconazole, NCT00859781
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: NHL16, NCI-2012-00496, NCT01451515
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: ALLR18, NCT01700946
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13026, CRAD001JUS240T, NCT02229136
Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: KSPHO_HRALL, NCT02339350
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RELMLL, NCI-2015-00602, NCT02419755
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: MITREL, NCI-2015-00691, NCT02433483
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
Phase: Phase I
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCC-OHN-GI-13, NCT01874860
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Phase: No phase specified
Type: Treatment
Status: Active
Age: 365 days and under
Sponsor: Other
Protocol IDs: CDR0000570260, DCOG-INTERFANT-06, EUDRACT-2005-004599-19, CCLG-LK-2006-10, NCT00550992
Start Over